Naloxone

"Naloxone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors.

Descriptor ID	D009270
MeSH Number(s)	D03.132.577.249.706 D03.605.497.750 D03.633.400.686.750 D04.615.723.795.706
Concept/Terms	Naloxone Naloxone Nalone Nalone Naloxon Curamed Naloxon Curamed Curamed, Naloxon Naloxon-Ratiopharm Naloxon-Ratiopharm Naloxon Ratiopharm Naloxone Abello Naloxone Abello Abello, Naloxone Naloxone Hydrochloride Naloxone Hydrochloride Hydrochloride, Naloxone Naloxone Hydrochloride Dihydride Naloxone Hydrochloride Dihydride Dihydride, Naloxone Hydrochloride Hydrochloride Dihydride, Naloxone Naloxone Hydrochloride, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer Naloxone Hydrochloride, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer Naloxone, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer Naloxone, (5 beta,9 alpha,13 alpha,14 alpha)-Isomer Narcan Narcan Narcanti MRZ-2593 MRZ-2593 MRZ 2593 MRZ2593 MRZ 2593-Br MRZ 2593 Br MRZ 2593Br Naloxone Hydrobromide Naloxone Hydrobromide Hydrobromide, Naloxone

Below are MeSH descriptors whose meaning is more general than "Naloxone".

Chemicals and Drugs [D]
Heterocyclic Compounds [D03]
Alkaloids [D03.132]
Opiate Alkaloids [D03.132.577]
Morphinans [D03.132.577.249]
Naloxone [D03.132.577.249.706]
Heterocyclic Compounds, Bridged-Ring [D03.605]
Morphinans [D03.605.497]
Naloxone [D03.605.497.750]
Heterocyclic Compounds, Fused-Ring [D03.633]
Heterocyclic Compounds, 4 or More Rings [D03.633.400]
Morphinans [D03.633.400.686]
Naloxone [D03.633.400.686.750]
Polycyclic Compounds [D04]
Polycyclic Aromatic Hydrocarbons [D04.615]
Phenanthrenes [D04.615.723]
Morphinans [D04.615.723.795]
Naloxone [D04.615.723.795.706]

Below are MeSH descriptors whose meaning is related to "Naloxone".

Below are MeSH descriptors whose meaning is more specific than "Naloxone".

Naloxone
Buprenorphine, Naloxone Drug Combination
Naltrexone

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Naloxone" by people in this website by year, and whether "Naloxone" was a major or minor topic of these publications.

Bar chart showing 32 publications over 20 distinct years, with a maximum of 5 publications in 2023

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2001	1	0	1
2002	0	1	1
2004	0	1	1
2008	2	0	2
2009	1	0	1
2010	0	1	1
2011	1	0	1
2012	1	1	2
2013	1	0	1
2014	1	0	1
2015	1	0	1
2016	0	1	1
2017	0	2	2
2018	1	0	1
2019	1	1	2
2020	1	1	2
2021	2	0	2
2022	0	2	2
2023	0	5	5
2024	0	2	2

Below are the most recent publications written about "Naloxone" by people in Profiles.

Christine PJ, Lodi S, Hsu HE, Bovell-Ammon B, Yan S, Bernson D, Novo P, Lee JD, Rotrosen J, Liebschutz J, Walley AY, Larochelle MR. Target trial emulation for comparative effectiveness research with observational data: Promise and challenges for studying medications for opioid use disorder. Addiction. 2024 07; 119(7):1313-1321.

View in: PubMed
Westafer LM, Beck SA, Simon C, Potee B, Soares WE, Schoenfeld EM. Barriers and Facilitators to Harm Reduction for Opioid Use Disorder: A Qualitative Study of People With Lived Experience. Ann Emerg Med. 2024 Apr; 83(4):340-350.

View in: PubMed
Hoover DB, Korthuis PT, Waddell EN, Foot C, Conway C, Crane HM, Friedmann PD, Go VF, Nance RM, Pho MT, Satcher MF, Sibley A, Westergaard RP, Young AM, Cook R. Recent Incarceration, Substance Use, Overdose, and Service Use Among People Who Use Drugs in Rural Communities. JAMA Netw Open. 2023 11 01; 6(11):e2342222.

View in: PubMed
Davis A, Stringer KL, Drainoni ML, Oser CB, Knudsen HK, Aldrich A, Surratt HL, Walker DM, Gilbert L, Downey DL, Gardner SD, Tan S, Lines LM, Vandergrift N, Mack N, Holloway J, Lunze K, McAlearney AS, Huerta TR, Goddard-Eckrich DA, El-Bassel N. Community-level determinants of stakeholder perceptions of community stigma toward people with opioid use disorders, harm reduction services and treatment in the HEALing Communities Study. Int J Drug Policy. 2023 Dec; 122:104241.

View in: PubMed
Pepin MD, Joseph JK, Chapman BP, McAuliffe C, O'Donnell LK, Marano RL, Carreiro SP, Garcia EJ, Silk H, Babu KM. A mobile addiction service for community-based overdose prevention. Front Public Health. 2023; 11:1154813.

View in: PubMed
Argenyi MS, Evans JK, Gay Y, Epstein DH, Weiss ST. The Opioid Overdose Resuscitation Education for Addiction Counselors and Trainees (Opioid Overdose REACT) naloxone response education pilot project improved confidence and knowledge among addiction counselors and trainees. Clin Toxicol (Phila). 2023 07; 61(7):509-517.

View in: PubMed
Friedmann PD, Jawa R, Wilson D, Ramsey SE, Hoskinson R, McKenzie M, Walley AY, Green TC, Bratberg J, Rich JD. Prescribe to Save Lives: An Intervention to Increase Naloxone Prescribing Among HIV Clinicians. J Addict Med. 2023 Sep-Oct 01; 17(5):598-603.

View in: PubMed
Randall A, Hull I, Martin SA. Enhancing Patient Choice: Using Self-administered Intranasal Naloxone for Novel Rapid Buprenorphine Initiation. J Addict Med. 2023 Mar-Apr 01; 17(2):237-240.

View in: PubMed
Nolte K, Romo E, Stopka TJ, Drew A, Dowd P, Del Toro-Mejias L, Bianchet E, Friedmann PD. "I've been to?more?of my friends'?funerals?than?I've been to my friends' weddings": Witnessing and responding to overdose in rural Northern New England. J Rural Health. 2023 01; 39(1):197-211.

View in: PubMed
Naber CE, Acholonu NO, Fernandes ND, Sanders BP, Sweetser L, Flaherty MR, Lahoud-Rahme M, Yager PH. Ventricular tachycardia after naloxone administration in an adolescent. Am J Emerg Med. 2021 Nov; 49:300-301.

View in: PubMed

People

Explore

Similar Concepts

Top Journals